Under the collaboration, Novo Nordisk will fund 10 Oxford researchers at the Kennedy Institute of Rheumatology to work within the partnership.
A Joint steering committee with members from both parties, including Per Falk and Professor Feldmann, will oversee the partnership and assess research proposals from scientists at both organizations.
Novo Nordisk biopharmaceutical research unit senior vice president Per Falk said, "The overall ambition is to combine our company’s clinical development strengths with those of the Kennedy Institute to increase the odds that we can successfully develop novel treatment regimens and get them more quickly to the patients who could potentially benefit from them."